Ex vivo stretch reveals altered mechanical properties of isolated dystrophin-deficient hearts

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Barnabei, Matthew S ^a   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SARCOGLYCAN; CALCIUM; DYSFERLIN; DYSTROPHIN; DYSTROPHIN ASSOCIATED PROTEIN COMPLEX; DYSTROPHIN GLYCOPROTEIN COMPLEX; LAMININ ALPHA2; UNCLASSIFIED DRUG; DYSF PROTEIN, MOUSE; LACTATE DEHYDROGENASE; LAMININ; MEMBRANE PROTEIN; SARCOGLYCAN;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL DEATH; CONTROLLED STUDY; DISEASE PREDISPOSITION; DUCHENNE MUSCULAR DYSTROPHY; EX VIVO STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE MUTATION; GENETIC MODEL; HEART DILATATION; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE DILATATION; HEART LEFT VENTRICLE DISTENTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; LAMA2 GENE; MECHANICAL STRESS; MOUSE MUTANT; NONHUMAN; PROTEIN EXPRESSION; SARCOMERE LENGTH; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; COMPLIANCE (PHYSICAL); CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SARCOMERE; STIMULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; COMPLIANCE; DYSTROPHIN; FLUORESCENT ANTIBODY TECHNIQUE; L-LACTATE DEHYDROGENASE; LAMININ; MEMBRANE PROTEINS; MICE; MICE, INBRED MDX; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCYTES, CARDIAC; PHYSICAL STIMULATION; SARCOGLYCANS; SARCOMERES; STRESS, MECHANICAL; VENTRICULAR FUNCTION, LEFT;

EID: 84857969551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032880     Document Type: Article

References (97)

1. Emery AE, (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1: 19-29.
2. Hoffman EP, Brown RH Jr, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
3. Davies KE, Pearson PL, Harper PS, Murray JM, O'Brien T, et al. (1983) Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res 11: 2303-2312.
4. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
5. Yoshida M, Ozawa E, (1990) Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 108: 748-752.
6. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP, (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315-319.
7. Ervasti JM, Campbell KP, (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122: 809-823.
8. Suzuki A, Yoshida M, Yamamoto H, Ozawa E, (1992) Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain. FEBS Lett 308: 154-160.
9. Hemmings L, Kuhlman PA, Critchley DR, (1992) Analysis of the actin-binding domain of alpha-actinin by mutagenesis and demonstration that dystrophin contains a functionally homologous domain. J Cell Biol 116: 1369-1380.
10. Way M, Pope B, Cross RA, Kendrick-Jones J, Weeds AG, (1992) Expression of the N-terminal domain of dystrophin in E. coli and demonstration of binding to F-actin. FEBS Lett 301: 243-245.
11. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, et al. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418: 417-422.
12. Vilquin JT, Brussee V, Asselin I, Kinoshita I, Gingras M, et al. (1998) Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 21: 567-576.
13. Weller B, Karpati G, Carpenter S, (1990) Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 100: 9-13.
14. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, et al. (2010) Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 120: 1140-1150.
15. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, et al. (2005) Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436: 1025-1029.
16. Fanchaouy M, Polakova E, Jung C, Ogrodnik J, Shirokova N, et al. (2009) Pathways of abnormal stress-induced Ca2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium 46: 114-121.
17. Xu Y, Delfin DA, Rafael-Fortney JA, Janssen PM, (2011) Lengthening-contractions in isolated myocardium impact force development and worsen cardiac contractile function in the mdx mouse model of muscular dystrophy. J Appl Physiol 110: 512-519.
18. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, et al. (2009) Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 80: 320-325.
19. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, et al. (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12: 926-929.
20. Finsterer J, Stollberger C, (2003) The heart in human dystrophinopathies. Cardiology 99: 1-19.
21. Gulati S, Saxena A, Kumar V, Kalra V, (2005) Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr 72: 389-393.
22. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, et al. (2007) Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17: 470-475.
23. Conte G, Gioia L, (1836) Scrofola del sistema muscolare. Annali Clinici dell'Ospedale degli Incurabili 66.
24. Spurney CF, (2011) Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44: 8-19.
25. McNally EM, (2007) New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu Rev Med 58: 75-88.
26. Cox GF, Kunkel LM, (1997) Dystrophies and heart disease. Curr Opin Cardiol 12: 329-343.
27. Nigro G, Comi LI, Politano L, Bain RJ, (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26: 271-277.
28. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, et al. (2004) Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14: 491-496.
29. Anversa P, Olivetti G, Capasso JM, (1991) Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 68: 7D-16D.
30. White HD, (1992) Remodelling of the heart after myocardial infarction. Aust N Z J Med 22: 601-606.
31. Francis GS, Chu C, (1995) Post-infarction myocardial remodelling: why does it happen? Eur Heart J 16 (Suppl N): 31-36.
32. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, et al. (1995) The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 27: 291-305.
33. Olivetti G, Melissari M, Capasso JM, Anversa P, (1991) Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 68: 1560-1568.
34. Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, et al. (1995) The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 92: 2306-2317.
35. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410-1413.
36. Day SM, Westfall MV, Fomicheva EV, Hoyer K, Yasuda S, et al. (2006) Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med 12: 181-189.
37. Bostick B, Yue Y, Long C, Duan D, (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin/utrophin expression. Circ Res 102: 121-130.
38. Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA, (2005) Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289: H2373-2378.
39. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, et al. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717-727.
40. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, et al. (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90: 729-738.
41. LeWinter MM, Wu Y, Labeit S, Granzier H, (2007) Cardiac titin: structure, functions and role in disease. Clin Chim Acta 375: 1-9.
42. Fukuda N, Terui T, Ishiwata S, Kurihara S, (2010) Titin-based regulations of diastolic and systolic functions of mammalian cardiac muscle. J Mol Cell Cardiol 48: 876-881.
43. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H, (2004) Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res 94: 505-513.
44. Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, et al. (1995) Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet 11: 257-265.
45. Bonnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, et al. (1995) Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet 11: 266-273.
46. Xu H, Wu XR, Wewer UM, Engvall E, (1994) Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene. Nat Genet 8: 297-302.
47. Hohenester E, Tisi D, Talts JF, Timpl R, (1999) The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin. Mol Cell 4: 783-792.
48. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, et al. (1995) Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 11: 216-218.
49. Liu J, Aoki M, Illa I, Wu C, Fardeau M, et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31-36.
50. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, et al. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168-172.
51. Brooks SV, (1998) Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice. J Muscle Res Cell Motil 19: 179-187.
52. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL, (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90: 3710-3714.
53. Menke A, Jockusch H, (1991) Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 349: 69-71.
54. Wilding JR, Schneider JE, Sang AE, Davies KE, Neubauer S, et al. (2005) Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 19: 79-81.
55. Vaghy PL, Fang J, Wu W, Vaghy LP, (1998) Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett 431: 125-127.
56. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, et al. (1997) Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 272: 25437-25440.
57. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, et al. (1996) Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271: 15160-15165.
58. Sinha B, Koster D, Ruez R, Gonnord P, Bastiani M, et al. (2011) Cells respond to mechanical stress by rapid disassembly of caveolae. Cell 144: 402-413.
59. Liang H, Muller J, Weng YG, Wallukat G, Fu P, et al. (2004) Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy. Chin Med J (Engl) 117: 401-407.
60. Marijianowski MM, Teeling P, Mann J, Becker AE, (1995) Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25: 1263-1272.
61. Yoshikane H, Honda M, Goto Y, Morioka S, Ooshima A, et al. (1992) Collagen in dilated cardiomyopathy-scanning electron microscopic and immunohistochemical observations. Jpn Circ J 56: 899-910.
62. Omens JH, Rockman HA, Covell JW, (1994) Passive ventricular mechanics in tight-skin mice. Am J Physiol 266: H1169-1176.
63. Van Erp C, Loch D, Laws N, Trebbin A, Hoey AJ, (2010) Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 42: 504-513.
64. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, et al. (2002) Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 106: 1384-1389.
65. Matsumura K, Shimizu T, Nonaka I, Mannen T, (1989) Immunochemical study of connectin (titin) in neuromuscular diseases using a monoclonal antibody: connectin is degraded extensively in Duchenne muscular dystrophy. J Neurol Sci 93: 147-156.
66. LeGrice IJ, Takayama Y, Covell JW, (1995) Transverse shear along myocardial cleavage planes provides a mechanism for normal systolic wall thickening. Circ Res 77: 182-193.
67. McCulloch AD, Smaill BH, Hunter PJ, (1989) Regional left ventricular epicardial deformation in the passive dog heart. Circ Res 64: 721-733.
68. Nielsen PM, Le Grice IJ, Smaill BH, Hunter PJ, (1991) Mathematical model of geometry and fibrous structure of the heart. Am J Physiol 260: H1365-1378.
69. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P, (1990) Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 67: 23-34.
70. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P, (1991) Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 68: 856-869.
71. Weisman HF, Bush DE, Mannisi JA, Weisfeldt ML, Healy B, (1988) Cellular mechanisms of myocardial infarct expansion. Circulation 78: 186-201.
72. Ross J Jr, Sonnenblick EH, Taylor RR, Spotnitz HM, Covell JW, (1971) Diastolic geometry and sarcomere lengths in the chronically dilated canine left ventricle. Circ Res 28: 49-61.
73. Vitali-Mazza L, Anversa P, Tedeschi F, Mastandrea R, Mavilla V, et al. (1972) Ultrastructural basis of acute left ventricular failure from severe acute aortic stenosis in the rabbit. J Mol Cell Cardiol 4: 661-671.
74. Lee GH, Badorff C, Knowlton KU, (2000) Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res 87: 489-495.
75. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, et al. (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5: 320-326.
76. Vatta M, Stetson SJ, Jimenez S, Entman ML, Noon GP, et al. (2004) Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol 43: 811-817.
77. Vatta M, Stetson SJ, Perez-Verdia A, Entman ML, Noon GP, et al. (2002) Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359: 936-941.
78. Toyo-Oka T, Kawada T, Nakata J, Xie H, Urabe M, et al. (2004) Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci U S A 101: 7381-7385.
79. Langendorff, (1895) Untersuchungen am überlebenden Säugetierherzen. Pflügers Archiv 61: 291-332.
80. Dhein S, Mohr FW, Delmar M, (2005) Practical Methods in Cardiovascular Research Springer.
81. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, et al. (2007) Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092.
82. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, et al. (2001) Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. Faseb J 15: 1655-1657.
83. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H, (2000) Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 32: 2151-2162.
84. Granzier HL, Labeit S, (2004) The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res 94: 284-295.
85. Araishi K, Sasaoka T, Imamura M, Noguchi S, Hama H, et al. (1999) Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice. Hum Mol Genet 8: 1589-1598.
86. Barresi R, Di Blasi C, Negri T, Brugnoni R, Vitali A, et al. (2000) Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet 37: 102-107.
87. Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F, (1998) Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. Am Heart J 136: 474-476.
88. Durbeej M, Cohn RD, Hrstka RF, Moore SA, Allamand V, et al. (2000) Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 5: 141-151.
89. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, et al. (2000) Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 113 (Pt 14): 2535-2544.
90. Hack AA, Cordier L, Shoturma DI, Lam MY, Sweeney HL, et al. (1999) Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A 96: 10723-10728.
91. Blaauw B, Agatea L, Toniolo L, Canato M, Quarta M, et al. (2010) Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J Appl Physiol 108: 105-111.
92. Straub V, Rafael JA, Chamberlain JS, Campbell KP, (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 139: 375-385.
93. Head SI, Bakker AJ, Liangas G, (2004) EDL and soleus muscles of the C57BL6J/dy2j laminin-alpha 2-deficient dystrophic mouse are not vulnerable to eccentric contractions. Exp Physiol 89: 531-539.
94. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, et al. (2005) Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 14: 1029-1040.
95. Colognato H, Yurchenco PD, (1999) The laminin alpha2 expressed by dystrophic dy(2J) mice is defective in its ability to form polymers. Curr Biol 9: 1327-1330.
96. Kuru S, Yasuma F, Wakayama T, Kimura S, Konagaya M, et al. (2004) [A patient with limb girdle muscular dystrophy type 2B (LGMD2B) manifesting cardiomyopathy]. Rinsho Shinkeigaku 44: 375-378.
97. Wenzel K, Geier C, Qadri F, Hubner N, Schulz H, et al. (2007) Dysfunction of dysferlin-deficient hearts. J Mol Med 85: 1203-1214.